Dr. Do-Youn Oh, MD
Claim this profileSeoul National University Hospital
Studies Stomach Cancer
Studies Cancer
26 reported clinical trials
50 drugs studied
Area of expertise
1Stomach Cancer
Stage IV
Stage III
HER2 positive
2Cancer
HER2 positive
Stage IV
Stage III
Clinical Trials Do-Youn Oh, MD is currently running
Tinengotinib
for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Recruiting2 awards Phase 3
CYC140
for Advanced Cancers and Lymphoma
This trial tests a new oral drug, CYC140, in patients with advanced cancers who have no other treatment options. It aims to see if the drug is safe and effective in stopping cancer growth or killing cancer cells.
Recruiting1 award Phase 1 & 2
More about Do-Youn Oh, MD
Clinical Trial Related3 years of experience running clinical trials · Led 26 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Do-Youn Oh, MD has experience with
- Capecitabine
- Gemcitabine
- ZW25 (Zanidatamab)
- Tucatinib
- Cisplatin
- Oxaliplatin
Breakdown of trials Do-Youn Oh, MD has run
Stomach Cancer
Cancer
Biliary Tract Cancer
Pancreatic Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Do-Youn Oh, MD specialize in?
Is Do-Youn Oh, MD currently recruiting for clinical trials?
Are there any treatments that Do-Youn Oh, MD has studied deeply?
What is the best way to schedule an appointment with Do-Youn Oh, MD?
What is the office address of Do-Youn Oh, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.